Stacey A Fedewa1, Ted Gansler2, Robert Smith3, Ann Goding Sauer2, Richard Wender3, Otis W Brawley4, Ahmedin Jemal2. 1. Intramural Research Department, American Cancer Society, Atlanta, Georiga stacey.fedewa@cancer.org. 2. Intramural Research Department, American Cancer Society, Atlanta, Georiga. 3. Cancer Control Department, American Cancer Society, Atlanta, Georgia. 4. Office of the Chief Medical Officer, American Cancer Society, Atlanta, Georgia.
Abstract
PURPOSE: Previous studies report infrequent use of shared decision making for prostate-specific antigen (PSA) testing. It is unknown whether this pattern has changed recently considering increased emphasis on shared decision making in prostate cancer screening recommendations. Thus, the objective of this study is to examine recent changes in shared decision making. METHODS: We conducted a retrospective cross-sectional study among men aged 50 years and older in the United States using 2010 and 2015 National Health Interview Survey (NHIS) data (n = 9,598). Changes in receipt of shared decision making were expressed as adjusted prevalence ratios (aPR) and 95% confidence intervals (CI). Analyses were stratified on PSA testing (recent [in the past year] or no testing). Elements of shared decision making assessed included the patient being informed about the advantages only, advantages and disadvantages, and full shared decision making (advantages, disadvantages, and uncertainties). RESULTS: Among men with recent PSA testing, 58.5% and 62.6% reported having received ≥1 element of shared decision making in 2010 and 2015, respectively (P = .054, aPR = 1.04; 95% CI, 0.98-1.11). Between 2010 and 2015, being told only about the advantages of PSA testing significantly declined (aPR = 0.82; 95% CI, 0.71-0.96) and full shared decision making prevalence significantly increased (aPR = 1.51; 95% CI, 1.28-1.79) in recently tested men. Among men without prior PSA testing, 10% reported ≥1 element of shared decision making, which did not change with time. CONCLUSION: Between 2010 and 2015, there was no increase in shared decision making among men with recent PSA testing though there was a shift away from only being told about the advantages of PSA testing towards full shared decision making. Many men receiving PSA testing did not receive shared decision making.
PURPOSE: Previous studies report infrequent use of shared decision making for prostate-specific antigen (PSA) testing. It is unknown whether this pattern has changed recently considering increased emphasis on shared decision making in prostate cancer screening recommendations. Thus, the objective of this study is to examine recent changes in shared decision making. METHODS: We conducted a retrospective cross-sectional study among men aged 50 years and older in the United States using 2010 and 2015 National Health Interview Survey (NHIS) data (n = 9,598). Changes in receipt of shared decision making were expressed as adjusted prevalence ratios (aPR) and 95% confidence intervals (CI). Analyses were stratified on PSA testing (recent [in the past year] or no testing). Elements of shared decision making assessed included the patient being informed about the advantages only, advantages and disadvantages, and full shared decision making (advantages, disadvantages, and uncertainties). RESULTS: Among men with recent PSA testing, 58.5% and 62.6% reported having received ≥1 element of shared decision making in 2010 and 2015, respectively (P = .054, aPR = 1.04; 95% CI, 0.98-1.11). Between 2010 and 2015, being told only about the advantages of PSA testing significantly declined (aPR = 0.82; 95% CI, 0.71-0.96) and full shared decision making prevalence significantly increased (aPR = 1.51; 95% CI, 1.28-1.79) in recently tested men. Among men without prior PSA testing, 10% reported ≥1 element of shared decision making, which did not change with time. CONCLUSION: Between 2010 and 2015, there was no increase in shared decision making among men with recent PSA testing though there was a shift away from only being told about the advantages of PSA testing towards full shared decision making. Many men receiving PSA testing did not receive shared decision making.
Authors: Kathryn L Taylor; Randi M Williams; Kimberly Davis; George Luta; Sofiya Penek; Samantha Barry; Scott Kelly; Catherine Tomko; Marc Schwartz; Alexander H Krist; Steven H Woolf; Mary B Fishman; Carmella Cole; Edward Miller Journal: JAMA Intern Med Date: 2013-10-14 Impact factor: 21.873
Authors: Karen R Sepucha; Leigh H Simmons; Michael J Barry; Susan Edgman-Levitan; Adam M Licurse; Sreekanth K Chaguturu Journal: Health Aff (Millwood) Date: 2016-04 Impact factor: 6.301
Authors: Vinay Prabhu; Ted Lee; Stacy Loeb; John H Holmes; Heather T Gold; Herbert Lepor; David F Penson; Danil V Makarov Journal: BJU Int Date: 2015-03-25 Impact factor: 5.588
Authors: Glyn Elwyn; Isabelle Scholl; Caroline Tietbohl; Mala Mann; Adrian G K Edwards; Catharine Clay; France Légaré; Trudy van der Weijden; Carmen L Lewis; Richard M Wexler; Dominick L Frosch Journal: BMC Med Inform Decis Mak Date: 2013-11-29 Impact factor: 2.796
Authors: Maja Elisabeth Juul Søndergaard; Kirsten Lode; Svein Reidar Kjosavik; Sissel Eikeland Husebø Journal: Scand J Prim Health Care Date: 2021-11-21 Impact factor: 2.581
Authors: Michelle M Kouspou; Jenna E Fong; Nadine Brew; Sarah T F Hsiao; Seanna L Davidson; Peter L Choyke; Tony Crispino; Suneil Jain; Guido W Jenster; Beatrice S Knudsen; Jeremy L Millar; Nicole Mittmann; Charles J Ryan; Bertrand Tombal; Mark Buzza Journal: Nat Rev Urol Date: 2020-07-22 Impact factor: 14.432